X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the partnership, Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC-derived NK Cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the selected therapeutic candidates.
Lead Product(s): Gene-edited iPSC-derived NK Cell
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Cellectis
Deal Size: $825.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration January 20, 2023
Details:
CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activation receptor NKp46.
Lead Product(s): CYT-338
Therapeutic Area: Oncology Product Name: CYT-338
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
CYT-338 is a tetravalent IgG1-like multifunctional NK cell engager antibody with a novel FLEX-linker that simultaneously binds CD38-expressing cells and NK cells via the activating receptor NKp46.
Lead Product(s): CYT-338
Therapeutic Area: Oncology Product Name: CYT-338
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
Cellectis has granted Cytovia a worldwide license under the patent rights over which Cellectis has control in this field, including in China, in order for Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer indications.
Lead Product(s): iPSC-derived NK Cells,Flex-NK Cell Engager
Therapeutic Area: Oncology Product Name: CYT-303
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Cellectis
Deal Size: $825.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration April 27, 2022
Details:
In addition, CYT-503, a GPC3-targeting CAR-iNK cell therapeutic, is designed to improve specificity for tumor targeting. Cytovia expects to file INDs for CYT-303 and CYT-100, followed by INDs for CYT-150 and CYT-503.
Lead Product(s): iPSC-derived NK Cells,Flex-NK Cell Engager
Therapeutic Area: Oncology Product Name: CYT-303
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Isleworth Healthcare Acquisition Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger April 26, 2022
Details:
First in vivo data demonstrated anti-tumor activity of Glypican-3 (GPC3) Flex-NK™ cell engager CYT-303 in combination with iNK cells in an animal model of Hepatocellular carcinoma (HCC).
Lead Product(s): CYT-303,iNK Cell
Therapeutic Area: Oncology Product Name: CYT-303
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
CYT 303 is a FLEX-NK® tetravalent bispecific trifunctional antibody targeting GPC3, a glycoprotein highly expressed on solid tumors, including Hepatocellular carcinoma, but not on adult healthy cells, is being developed to treat solid tumors expressing GPC3, including HCC.
Lead Product(s): CYT-303
Therapeutic Area: Oncology Product Name: CYT-303
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
Cellectis is granting Cytovia a worldwide license under the patent rights over which Cellectis has the control in this field, including in China, enabling Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer indications.
Lead Product(s): Gene-edited iPSC-derived NK cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Cellectis
Deal Size: $825.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 18, 2021
Details:
TF Capital, a leading China-based biotech institutional investor and Cytovia have formed CytoLynx Therapeutics, and invests to finance the IND enabling and initial clinical development of the pipeline programs including CYT-303.
Lead Product(s): CYT-303
Therapeutic Area: Oncology Product Name: CYT-303
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TF Capital
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 13, 2021
Details:
CytoLynx obtained a technology license from Cytovia based on its core technologies to allow in-China development of additional NK therapeutics for global commercialization including CYT-100.
Lead Product(s): CYT-100
Therapeutic Area: Oncology Product Name: CYT-100
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CytoLynx
Deal Size: Undisclosed Upfront Cash: $400.0 million
Deal Type: Collaboration September 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
